GOSTAR Content Updates - 2021
Published on 13-Sept-2021
GOSTAR is the largest manually annotated structure-activity relationships (SAR) database of small molecules published in mainstream medicinal chemistry journals and patents. Compounds from both discovery and development stages targeting all target families are covered. Along with SAR, key properties like ADME, and Toxicity are captured. This relational database enables users to navigate and analyze the massive content of small molecules to derive insightful decisions in the design and discovery of novel compounds.
Content Coverage
The GOSTAR database is composed of many different types of content, from the scientific literature to publicly available material.
- MedChem Journals
- Patents
- FDA/EMEA/PMDA Reports
- Clinical Trial Registries
- Scientific Reviews
- Company websites
- Books
- Conferences
- Public Sources
Preclinical Candidates Covered in 2021 (until July’2021)
In the year 2021, the GOSTAR database is enriched with various preclinical compounds acting against various indications like COVID-19, Non-alcoholic steatohepatitis (NASH), Hepatitis virus infections, HIV infections, Cardiovascular diseases, and various cancers.
Few significant drug inclusions until July 31, 2021:
- Synflorix
- AZD1222
- Benaglutide
- GSK-1557484A
- MRNA-1273
Target Space Covered in 2021 Updates
New content is updated for more than 2400 protein targets into the GOSTAR database until July 31, 2021.
Type of Content
Further deep analysis of the content covered in 2021 is shown in figure 2. Of the 1.2 million SAR rows added to GOSTAR, functional in-vitro and in-vivo contribute 41% to data, binding constitutes 33%, and 5% of content consists of ADME properties. 2% of content covers toxicity properties of compounds covered in 2021 and the rest 19% represents other property types including physicochemical properties.
